Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 70

1.

DNA topoisomerase-targeting chemotherapeutics: what's new?

Cuya SM, Bjornsti MA, van Waardenburg RCAM.

Cancer Chemother Pharmacol. 2017 Jul;80(1):1-14. doi: 10.1007/s00280-017-3334-5. Epub 2017 May 20. Review.

PMID:
28528358
2.

Molecular Mechanism of DNA Topoisomerase I-Dependent rDNA Silencing: Sir2p Recruitment at Ribosomal Genes.

D'Alfonso A, Di Felice F, Carlini V, Wright CM, Hertz MI, Bjornsti MA, Camilloni G.

J Mol Biol. 2016 Dec 4;428(24 Pt B):4905-4916. doi: 10.1016/j.jmb.2016.10.032. Epub 2016 Nov 5.

PMID:
27825925
3.

Acoustic Droplet Ejection Technology and Its Application in High-Throughput RNA Interference Screening.

Nebane NM, Coric T, McKellip S, Woods L, Sosa M, Rasmussen L, Bjornsti MA, White EL.

J Lab Autom. 2016 Feb;21(1):198-203. doi: 10.1177/2211068215620346. Epub 2015 Dec 9.

4.

Point mutations of the mTOR-RHEB pathway in renal cell carcinoma.

Ghosh AP, Marshall CB, Coric T, Shim EH, Kirkman R, Ballestas ME, Ikura M, Bjornsti MA, Sudarshan S.

Oncotarget. 2015 Jul 20;6(20):17895-910.

5.

DNA topoisomerase I domain interactions impact enzyme activity and sensitivity to camptothecin.

Wright CM, van der Merwe M, DeBrot AH, Bjornsti MA.

J Biol Chem. 2015 May 8;290(19):12068-78. doi: 10.1074/jbc.M114.635078. Epub 2015 Mar 20.

6.

Tyrosyl-DNA phosphodiesterase I catalytic mutants reveal an alternative nucleophile that can catalyze substrate cleavage.

Comeaux EQ, Cuya SM, Kojima K, Jafari N, Wanzeck KC, Mobley JA, Bjornsti MA, van Waardenburg RC.

J Biol Chem. 2015 Mar 6;290(10):6203-14. doi: 10.1074/jbc.M114.635284. Epub 2015 Jan 21.

7.

Development and histopathological characterization of tumorgraft models of pancreatic ductal adenocarcinoma.

Garcia PL, Council LN, Christein JD, Arnoletti JP, Heslin MJ, Gamblin TL, Richardson JH, Bjornsti MA, Yoon KJ.

PLoS One. 2013 Oct 23;8(10):e78183. doi: 10.1371/journal.pone.0078183. eCollection 2013.

8.

4-Hydroxytamoxifen induces autophagic death through K-Ras degradation.

Kohli L, Kaza N, Coric T, Byer SJ, Brossier NM, Klocke BJ, Bjornsti MA, Carroll SL, Roth KA.

Cancer Res. 2013 Jul 15;73(14):4395-405. doi: 10.1158/0008-5472.CAN-12-3765. Epub 2013 May 30.

9.

High-throughput RNA interference screening: tricks of the trade.

Nebane NM, Coric T, Whig K, McKellip S, Woods L, Sosa M, Sheppard R, Rasmussen L, Bjornsti MA, White EL.

J Lab Autom. 2013 Aug;18(4):334-9. doi: 10.1177/2211068213486786. Epub 2013 Apr 24.

10.

Cellular strategies for regulating DNA supercoiling: a single-molecule perspective.

Koster DA, Crut A, Shuman S, Bjornsti MA, Dekker NH.

Cell. 2010 Aug 20;142(4):519-30. doi: 10.1016/j.cell.2010.08.001. Review.

11.

Disulfide cross-links reveal conserved features of DNA topoisomerase I architecture and a role for the N terminus in clamp closure.

Palle K, Pattarello L, van der Merwe M, Losasso C, Benedetti P, Bjornsti MA.

J Biol Chem. 2008 Oct 10;283(41):27767-75. doi: 10.1074/jbc.M804826200. Epub 2008 Aug 8.

12.

Mutation of Gly721 alters DNA topoisomerase I active site architecture and sensitivity to camptothecin.

van der Merwe M, Bjornsti MA.

J Biol Chem. 2008 Feb 8;283(6):3305-15. Epub 2007 Dec 4.

13.

Mutation of a conserved active site residue converts tyrosyl-DNA phosphodiesterase I into a DNA topoisomerase I-dependent poison.

He X, van Waardenburg RC, Babaoglu K, Price AC, Nitiss KC, Nitiss JL, Bjornsti MA, White SW.

J Mol Biol. 2007 Sep 28;372(4):1070-81. Epub 2007 Aug 2.

PMID:
17707402
14.

TOR signaling is a determinant of cell survival in response to DNA damage.

Shen C, Lancaster CS, Shi B, Guo H, Thimmaiah P, Bjornsti MA.

Mol Cell Biol. 2007 Oct;27(20):7007-17. Epub 2007 Aug 13.

15.

Antitumour drugs impede DNA uncoiling by topoisomerase I.

Koster DA, Palle K, Bot ES, Bjornsti MA, Dekker NH.

Nature. 2007 Jul 12;448(7150):213-7. Epub 2007 Jun 24.

PMID:
17589503
16.

Structure of a SUMO-binding-motif mimic bound to Smt3p-Ubc9p: conservation of a non-covalent ubiquitin-like protein-E2 complex as a platform for selective interactions within a SUMO pathway.

Duda DM, van Waardenburg RC, Borg LA, McGarity S, Nourse A, Waddell MB, Bjornsti MA, Schulman BA.

J Mol Biol. 2007 Jun 8;369(3):619-30. Epub 2007 Apr 10.

17.

Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds: importance of vicinal cysteines 504 and 505.

Montaudon D, Palle K, Rivory LP, Robert J, Douat-Casassus C, Quideau S, Bjornsti MA, Pourquier P.

J Biol Chem. 2007 May 11;282(19):14403-12. Epub 2007 Mar 12.

18.

Alterations in linker flexibility suppress DNA topoisomerase I mutant-induced cell lethality.

Losasso C, Cretaio E, Palle K, Pattarello L, Bjornsti MA, Benedetti P.

J Biol Chem. 2007 Mar 30;282(13):9855-64. Epub 2007 Feb 2.

19.

Analysis of comptothecin resistance in yeast: relevance to cancer therapy.

Benedetti P, Benchokroun Y, Houghton PJ, Bjornsti MA.

Drug Resist Updat. 1998;1(3):176-83.

PMID:
17092803
20.

Distinct functional domains of Ubc9 dictate cell survival and resistance to genotoxic stress.

van Waardenburg RC, Duda DM, Lancaster CS, Schulman BA, Bjornsti MA.

Mol Cell Biol. 2006 Jul;26(13):4958-69.

21.

Trapping of DNA topoisomerase I on nick-containing DNA in cell free extracts of Saccharomyces cerevisiae.

Lebedeva N, Auffret Vander Kemp P, Bjornsti MA, Lavrik O, Boiteux S.

DNA Repair (Amst). 2006 Jul 13;5(7):799-809. Epub 2006 May 19.

PMID:
16713756
22.

Defects in SUMO (small ubiquitin-related modifier) conjugation and deconjugation alter cell sensitivity to DNA topoisomerase I-induced DNA damage.

Jacquiau HR, van Waardenburg RC, Reid RJ, Woo MH, Guo H, Johnson ES, Bjornsti MA.

J Biol Chem. 2005 Jun 24;280(25):23566-75. Epub 2005 Apr 6.

23.

Enhanced antitumor activity of irofulven in combination with irinotecan in pediatric solid tumor xenograft models.

Woo MH, Peterson JK, Billups C, Liang H, Bjornsti MA, Houghton PJ.

Cancer Chemother Pharmacol. 2005 May;55(5):411-9. Epub 2004 Oct 16.

PMID:
15503024
24.

Substitution of conserved residues within the active site alters the cleavage religation equilibrium of DNA topoisomerase I.

Colley WC, van der Merwe M, Vance JR, Burgin AB Jr, Bjornsti MA.

J Biol Chem. 2004 Dec 24;279(52):54069-78. Epub 2004 Oct 15.

25.

Platinated DNA adducts enhance poisoning of DNA topoisomerase I by camptothecin.

van Waardenburg RC, de Jong LA, van Eijndhoven MA, Verseyden C, Pluim D, Jansen LE, Bjornsti MA, Schellens JH.

J Biol Chem. 2004 Dec 24;279(52):54502-9. Epub 2004 Oct 6.

26.

Lost in translation: dysregulation of cap-dependent translation and cancer.

Bjornsti MA, Houghton PJ.

Cancer Cell. 2004 Jun;5(6):519-23. Review.

27.

The TOR pathway: a target for cancer therapy.

Bjornsti MA, Houghton PJ.

Nat Rev Cancer. 2004 May;4(5):335-48. Review. No abstract available.

PMID:
15122205
28.

Homologous recombination is a highly conserved determinant of the synergistic cytotoxicity between cisplatin and DNA topoisomerase I poisons.

van Waardenburg RC, de Jong LA, van Delft F, van Eijndhoven MA, Bohlander M, Bjornsti MA, Brouwer J, Schellens JH.

Mol Cancer Ther. 2004 Apr;3(4):393-402.

29.

The deubiquitinating enzyme Doa4p protects cells from DNA topoisomerase I poisons.

Fiorani P, Reid RJ, Schepis A, Jacquiau HR, Guo H, Thimmaiah P, Benedetti P, Bjornsti MA.

J Biol Chem. 2004 May 14;279(20):21271-81. Epub 2004 Feb 26.

30.

Locking the DNA topoisomerase I protein clamp inhibits DNA rotation and induces cell lethality.

Woo MH, Losasso C, Guo H, Pattarello L, Benedetti P, Bjornsti MA.

Proc Natl Acad Sci U S A. 2003 Nov 25;100(24):13767-72. Epub 2003 Oct 29.

31.

Rapamycins: mechanism of action and cellular resistance.

Huang S, Bjornsti MA, Houghton PJ.

Cancer Biol Ther. 2003 May-Jun;2(3):222-32. Review.

PMID:
12878853
32.

Overexpression and purification of DNA topoisomerase I from yeast.

Bjornsti MA, Fertala J.

Methods Mol Biol. 1999;94:179-86. No abstract available.

PMID:
12844874
33.

Resolution of DNA molecules by one-dimensional agarose-gel electrophoresis.

Bjornsti MA, Megonigal MD.

Methods Mol Biol. 1999;94:9-17. No abstract available.

PMID:
12844857
34.

Introduction to DNA topoisomerases.

Bjornsti MA, Osheroff N.

Methods Mol Biol. 1999;94:1-8. Review. No abstract available.

PMID:
12844856
35.

A novel active DNA topoisomerase I in Leishmania donovani.

Villa H, Otero Marcos AR, Reguera RM, Balaña-Fouce R, García-Estrada C, Pérez-Pertejo Y, Tekwani BL, Myler PJ, Stuart KD, Bjornsti MA, Ordóñez D.

J Biol Chem. 2003 Feb 7;278(6):3521-6. Epub 2002 Nov 19.

36.

Cancer therapeutics in yeast.

Bjornsti MA.

Cancer Cell. 2002 Oct;2(4):267-73. Review.

37.

Active site mutations in DNA topoisomerase I distinguish the cytotoxic activities of camptothecin and the indolocarbazole, rebeccamycin.

Woo MH, Vance JR, Marcos AR, Bailly C, Bjornsti MA.

J Biol Chem. 2002 Feb 8;277(6):3813-22. Epub 2001 Dec 3.

38.

Mechanisms of DNA topoisomerase I-induced cell killing in the yeast Saccharomyces cerevisiae.

Fiorani P, Bjornsti MA.

Ann N Y Acad Sci. 2000;922:65-75. Review.

PMID:
11193926
39.

Studying DNA topoisomerase I-targeted drugs in the yeast. Saccharomyces cerevisiae.

Woo MH, Vance JR, Bjornsti MA.

Methods Mol Biol. 2001;95:303-13. No abstract available.

PMID:
11089242
40.

Drug-induced stabilization of covalent DNA topoisomerase I-DNA intermediates. DNA cleavage assays.

Fiorani P, Hann CL, Benedetti P, Bjornsti MA.

Methods Mol Biol. 2001;95:291-301. No abstract available.

PMID:
11089241
41.
42.

Domain interactions affecting human DNA topoisomerase I catalysis and camptothecin sensitivity.

Fiorani P, Amatruda JF, Silvestri A, Butler RH, Bjornsti MA, Benedetti P.

Mol Pharmacol. 1999 Dec;56(6):1105-15.

43.

CDC45 and DPB11 are required for processive DNA replication and resistance to DNA topoisomerase I-mediated DNA damage.

Reid RJ, Fiorani P, Sugawara M, Bjornsti MA.

Proc Natl Acad Sci U S A. 1999 Sep 28;96(20):11440-5.

44.

Induction of reversible complexes between eukaryotic DNA topoisomerase I and DNA-containing oxidative base damages. 7, 8-dihydro-8-oxoguanine and 5-hydroxycytosine.

Pourquier P, Ueng LM, Fertala J, Wang D, Park HJ, Essigmann JM, Bjornsti MA, Pommier Y.

J Biol Chem. 1999 Mar 26;274(13):8516-23.

45.

Cascades of mammalian caspase activation in the yeast Saccharomyces cerevisiae.

Kang JJ, Schaber MD, Srinivasula SM, Alnemri ES, Litwack G, Hall DJ, Bjornsti MA.

J Biol Chem. 1999 Jan 29;274(5):3189-98.

46.

Intragenic suppressors of mutant DNA topoisomerase I-induced lethality diminish enzyme binding of DNA.

Hann CL, Carlberg AL, Bjornsti MA.

J Biol Chem. 1998 Nov 20;273(47):31519-27.

47.

Induction of topoisomerase I cleavage complexes by the vinyl chloride adduct 1,N6-ethenoadenine.

Pourquier P, Bjornsti MA, Pommier Y.

J Biol Chem. 1998 Oct 16;273(42):27245-9.

48.

Yeast as a model organism for studying the actions of DNA topoisomerase-targeted drugs.

Reid RJ, Benedetti P, Bjornsti MA.

Biochim Biophys Acta. 1998 Oct 1;1400(1-3):289-300. Review.

PMID:
9748633
49.

Increased camptothecin toxicity induced in mammalian cells expressing Saccharomyces cerevisiae DNA topoisomerase I.

Hann C, Evans DL, Fertala J, Benedetti P, Bjornsti MA, Hall DJ.

J Biol Chem. 1998 Apr 3;273(14):8425-33.

50.

Alterations in the catalytic activity of yeast DNA topoisomerase I result in cell cycle arrest and cell death.

Megonigal MD, Fertala J, Bjornsti MA.

J Biol Chem. 1997 May 9;272(19):12801-8.

Supplemental Content

Loading ...
Support Center